Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adipose-derived mesenchymal stem cells secretome
- Development stage
- Unknown
- Lead developer
- Dr. Cipto Mangunkusumo Hospital
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
Adipose-derived mesenchymal stem cells secretome (ADMSCS) is a cell-free biologic therapeutic derived from the conditioned medium of mesenchymal stem cells (MSCs) obtained from adipose tissue. Developed by Indonesia University and Dr. Cipto Mangunkusumo Hospital, the secretome contains a complex mixture of bioactive molecules, including growth factors (such as TGF-beta 3), cytokines, and extracellular vesicles (exosomes and microvesicles). In the treatment of melasma, the secretome exerts a depigmenting effect by modulating tissue formation and inhibiting melanogenesis. Specifically, components like TGF-beta 3 suppress the expression of microphthalmia-associated transcription factor (MITF) via the ERK signaling pathway, leading to reduced tyrosinase activity and melanin accumulation. The product is typically administered via intradermal injection.
- Other names
- stem cell conditioned mediumADMSC secretomeconcentrated secretome
02
Targets
TYR (Tyrosinase)MITF (Melanocyte inducing transcription factor)TGFBR (TGF-beta receptor)
Beyond the preview
Go deeper on adipose-derived mesenchymal stem cells secretome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adipose-derived mesenchymal stem cells secretome.